PA
TTNP

Pinnacle Associates’s Titan Pharmaceuticals TTNP Stock Holding History

Pinnacle Associates’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-33
Closed -$6K – 697
2020
Q2 		$6K Buy
+33
New +$5.68K ﹤0.01% 673

Other funds holding TTNP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Pinnacle Associates's TTNP Position: Q3 2020 in Review

Pinnacle Associates sold out of Titan Pharmaceuticals (TTNP) in Q3 2020, closing a stake of 33 shares — an estimated $6K sold.

Pinnacle Associates first reported a position in TTNP in Q2 2020 and held it in 1 quarter. The position peaked at $6K in Q2 2020. 16 funds tracked by Wall St. Rank hold TTNP as of Q3 2020.

  • Pinnacle Associates reported no remaining Titan Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Pinnacle Associates sold 33 Titan Pharmaceuticals shares in Q3 2020, an estimated $6K.
  • Pinnacle Associates first reported a position in Titan Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Pinnacle Associates's Titan Pharmaceuticals position peaked at $6K in Q2 2020.
  • 16 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2020.

Based on Pinnacle Associates's 13F filing for Q3 2020, filed 23 Oct 2020.